Induced sputum matrix metalloproteinase‐9 correlates with lung function and airway inflammation in children with cystic fibrosis

Matrix metalloproteinases (MMPs) degrade extracellular matrix and are implicated in causing airway damage in chronic inflammatory lung diseases, including cystic fibrosis (CF). Our primary objective was to examine the relationship between matrix metalloproteinase‐9 (MMP‐9) and pulmonary function, as measured by forced expiratory volume in 1 sec (FEV1), in children with CF. We measured MMP‐9 and its natural tissue inhibitor of metalloproteinase‐1 (TIMP‐1) in induced sputum from 18 clinically stable CF children with normal to mildly abnormal lung function and 7 healthy control children. Measures of airway inflammation from induced sputum included cell counts and differentials, interleukin‐8 (IL‐8), neutrophil elastase, MMP‐9, and TIMP‐1. Infection was assessed through quantitative bacterial counts. Induced sputum levels of MMP‐9 and TIMP‐1 were significantly increased in children with CF compared with healthy controls. Also, the MMP‐9/TIMP‐1 molar ratio was higher in the CF group. Among CF children, there was a significant inverse relationship between MMP‐9 and FEV1. In addition, sputum MMP‐9 and TIMP‐1 concentrations significantly correlated with total white cells and neutrophils, IL‐8, and neutrophil elastase. Neither MMP‐9 nor TIMP‐1 correlated with airway infection. We conclude that clinically stable CF children with normal to mildly abnormal lung function have an increased burden of MMP‐9 in their airways. The observed relationships of MMP‐9 with lung function and other measures of airway inflammation suggest that this enzyme may be a useful marker of airway injury and airflow obstruction in persons with CF. Pediatr Pulmonol. 2005; 39:224–232. © 2005 Wiley‐Liss, Inc.

[1]  R. Gibson,et al.  Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[2]  R. Buhl,et al.  Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. , 2003, Respiratory medicine.

[3]  S. Wenzel,et al.  Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. , 2003, The Journal of allergy and clinical immunology.

[4]  Z. Han,et al.  Expression of matrix metalloproteinases MMP-9 within the airways in asthma. , 2003, Respiratory medicine.

[5]  P. Gibson,et al.  Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis , 2003, European Respiratory Journal.

[6]  C. Metcalfe,et al.  Safety and use of sputum induction in children with cystic fibrosis , 2003, Pediatric pulmonology.

[7]  N. Jarjour,et al.  Role of matrix metalloproteinases in asthma , 2003, Current opinion in pulmonary medicine.

[8]  F. Accurso,et al.  Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. , 2002, The Journal of pediatrics.

[9]  K. Chung,et al.  Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. , 2002, Chest.

[10]  F. Ratjen,et al.  Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha , 2002, Thorax.

[11]  G. Tipoe,et al.  Overexpression of matrix metalloproteinase‐8 and ‐9 in bronchiectatic airways in vivo , 2002, European Respiratory Journal.

[12]  P. Barnes,et al.  Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory cell and molecular biology.

[13]  J. Shute.  Matrix metalloproteinase‐9: marker or mediator of tissue damage in asthma? , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  F. Accurso,et al.  Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. , 2001, American journal of respiratory and critical care medicine.

[15]  H. Boushey,et al.  Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study * , 2001, Pediatric pulmonology.

[16]  J. Burns,et al.  Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis , 2001, Thorax.

[17]  T. Ochi,et al.  Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. , 2001, Rheumatology.

[18]  K. Takagi,et al.  Matrix Metalloproteinases and Tissue lnhibitors of Matrix Metalloproteinases in Sputum from Patients with Bronchial Asthma , 2001 .

[19]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[20]  J. Foidart,et al.  MMP-2- and MMP-9-Linked Gelatinolytic Activity in the Sputum from Patients with Asthma and Chronic Obstructive Pulmonary Disease , 2000, International Archives of Allergy and Immunology.

[21]  Z. Werb,et al.  The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.

[22]  Y. Okada,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.

[23]  Hiroshi Tanaka,et al.  Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. , 2000, The Journal of allergy and clinical immunology.

[24]  J. Bousquet,et al.  Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.

[25]  B. Dahlén,et al.  Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma , 1999, Thorax.

[26]  A. Harf,et al.  Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. , 1999, American journal of respiratory cell and molecular biology.

[27]  D. Hartmann,et al.  Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. , 1999, American journal of respiratory and critical care medicine.

[28]  J. Bousquet,et al.  Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[29]  S. Isogai,et al.  Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. , 1998, The Journal of allergy and clinical immunology.

[30]  J. Emerson,et al.  Microbiology of sputum from patients at cystic fibrosis centers in the United States. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  G. Cutting,et al.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. , 1998, The Journal of pediatrics.

[32]  Melvin Berger,et al.  Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology , 1997, Pediatric pulmonology.

[33]  C. O'connor,et al.  Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. , 1997, Thorax.

[34]  W. Maloney,et al.  Osteoarthritis: Differential expression of matrix metalloproteinase‐9 mRNA in nonfibrillated and fibrillated cartilage , 1997, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[35]  L. Liotta,et al.  Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. , 1996, The American journal of pathology.

[36]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[37]  C. Delacourt,et al.  Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[38]  M. Konstan,et al.  Elastin and collagen degradation products in urine of patients with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[39]  R. Sepper,et al.  Gelatinolytic and type IV collagenolytic activity in bronchiectasis. , 1994, Chest.

[40]  J. Hayes,et al.  Neutrophil collagenase in sputum from patients with cystic fibrosis. , 1994, American journal of respiratory and critical care medicine.

[41]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[42]  W. Stetler-Stevenson,et al.  Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. , 1993, The Journal of clinical investigation.

[43]  W. Calhoun,et al.  Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. , 1991, The American review of respiratory disease.

[44]  J. Pelletier,et al.  Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. , 1989, The Journal of clinical investigation.

[45]  J. Travis,et al.  Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases , 1988, FEBS letters.

[46]  S. Suter,et al.  Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. , 1986, The Journal of infectious diseases.

[47]  M. Baggiolini,et al.  Partial purification of collagenase and gelatinase from human polymorphonuclear leucocytes. Analysis of their actions on soluble and insoluble collagens. , 1982, The Biochemical journal.

[48]  S. Greenberg,et al.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. , 1976, Human pathology.